StreetInsider.com News Articles

Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: Moore David Scott

Mon, 15 Jun 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260615/26648538.html

Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: Moore David Scott

Mon, 15 Jun 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260615/26648538.html

Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: CLARK IAN T

Mon, 15 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26648518.html

Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: CLARK IAN T

Mon, 15 Jun 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260615/26648518.html

Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: Grais Linda

Mon, 15 Jun 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260615/26648486.html

Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: Grais Linda

Mon, 15 Jun 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260615/26648486.html

Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: Thompson Peter A.

Mon, 15 Jun 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260615/26648470.html

Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: Thompson Peter A.

Mon, 15 Jun 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260615/26648470.html

Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: van den Broek Richard

Mon, 15 Jun 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260615/26648431.html

Form 4 Corvus Pharmaceuticals, For: Jun 11 Filed by: van den Broek Richard

Mon, 15 Jun 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260615/26648431.html

Form 8-K Corvus Pharmaceuticals, For: Jun 11

Fri, 12 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260612/26640524.html

Form 8-K Corvus Pharmaceuticals, For: Jun 11

Fri, 12 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260612/26640524.html

Corvus Pharmaceuticals invests $5 million in Angel Pharmaceuticals

Tue, 09 Jun 2026 07:30:37 -0400

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) announced it participated in a $13.5 million financing round for Angel Pharmaceuticals Ltd., its collaboration partner in China. Corvus invested $5 million in the financing and remains Angel Pharma's largest shareholder.

The funding will support Angel Pharma's ongoing Phase 1b/2 trial of soquelitinib for atopic dermatitis and a planned Phase 2 trial for asthma. Angel Pharma expects to report results from the initial cohort of the atopic dermatitis trial in late 2026 and initiate the asthma trial in early 2027.

Angel Pharma is enrolling a blinded, placebo-controlled trial evaluating soquelitinib in 48 patients with moderate-to-severe atopic dermatitis

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Tue, 09 Jun 2026 07:30:00 -0400

SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13.5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the Company’s collaboration partner in China. Corvus co-founded Angel Pharma in 2020 to enable the clinical development and commercialization of its pipeline in China as well as the development of other novel drugs. Corvus is Angel Pharma’s largest shareholder and is investing $5 million in the current financing.

The funding is anticipated to support Angel Pharma’s ongoing Phase 1b/2

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Tue, 09 Jun 2026 07:30:00 -0400

The funding is anticipated to support Angel Pharma’s ongoing Phase 1b/2

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Tue, 09 Jun 2026 07:30:00 -0400

The funding is anticipated to support Angel Pharma’s ongoing Phase 1b/2

Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China

Tue, 09 Jun 2026 07:30:00 -0400

The funding is anticipated to support Angel Pharma’s ongoing Phase 1b/2

Form 4 Corvus Pharmaceuticals, For: May 18 Filed by: MILLER RICHARD A MD

Wed, 20 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260520/26528457.html

Form 4 Corvus Pharmaceuticals, For: May 18 Filed by: MILLER RICHARD A MD

Wed, 20 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260520/26528457.html

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 16:01:00 -0400

SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026 Jefferies Global Healthcare Conference, to be held in New York, NY, and the Goldman Sachs 47th Annual Global Healthcare Conference, to be held in Miami, FL. The Jefferies presentation is scheduled for Wednesday, June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is scheduled for Monday, June 8, 2026 at 11:20 AM ET.

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 16:01:00 -0400

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 16:01:00 -0400

Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Wed, 20 May 2026 16:01:00 -0400

Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260515/26505754.html

Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: Point72 Asset Management, L.P.

Fri, 15 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260515/26505754.html